With its biggest revenue driver gRevlimid nearing the end of its high margin run, Dr. Reddy’s Laboratories is banking on new launches, pipeline expansion, and cost optimisation to sustain growth across global markets. The company expects upcoming products such as Semaglutide and Abatacept, along with the recently acquired Stugeron® portfolio, to support its next phase of expansion, even as analysts caution about near-term margin pressure. Advertisement

gRevlimid, the generic version of Bristol Myers Squibb’s blockbuster cancer drug Revlimid (lenalidomide), has been one of Dr. Reddy’s largest contributors in the US market since its launch. The drug, used in the treatment of multiple myeloma, has generated strong profits for Indian generics players since 2022, but its exclusivity window is

See Full Page